Summary
AbbVie Inc. (ABBV) has filed a Form 8-K disclosing preliminary financial information and guidance updates for the fourth quarter and full year 2025. The company expects to report significant acquired In-Process Research & Development (IPR&D) and milestones expenses totaling $1.3 billion pre-tax for the fourth quarter of 2025. This expense is anticipated to have an unfavorable impact of $0.71 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. This disclosure impacts AbbVie's previously issued guidance. The full-year 2025 adjusted diluted earnings per share guidance has been revised to a range of $9.90 to $9.94, incorporating this expense. Similarly, the fourth-quarter 2025 adjusted diluted earnings per share guidance is now projected to be between $2.61 and $2.65. Investors should note that these figures are preliminary and subject to change as financial closing procedures are completed. The company also reiterates its cautionary note regarding forward-looking statements and the inherent risks and uncertainties in its business operations.
Key Highlights
- 1AbbVie expects $1.3 billion in acquired IPR&D and milestones expense for Q4 2025 (pre-tax).
- 2This expense negatively impacts Q4 2025 GAAP and adjusted non-GAAP diluted EPS by an estimated $0.71 per share.
- 3Full-year 2025 adjusted diluted EPS guidance is updated to a range of $9.90 - $9.94.
- 4Q4 2025 adjusted diluted EPS guidance is revised to a range of $2.61 - $2.65.
- 5The company emphasizes that these results are preliminary estimates and subject to financial statement closing procedures.
- 6Acquired IPR&D and milestones expenses are inherently unpredictable and not typically forecasted by AbbVie.